Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Status
- TERMINATED
- Phase
- PHASE3
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
- Status
- COMPLETED
- Phase
- PHASE3
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Status
- COMPLETED
- Phase
- PHASE3
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions
- Status
- UNKNOWN
- Phase
- PHASE3
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
- Status
- COMPLETED
- Phase
- PHASE4